Can TMS Help Dementia?
Yes, repetitive transcranial magnetic stimulation (rTMS) can provide modest cognitive benefits for patients with mild to moderate Alzheimer's disease, but it is not ready for routine clinical use and should currently be considered investigational. 1
Evidence for Cognitive Benefit
The most recent comprehensive evidence from 2026 demonstrates that rTMS appears safe in the short term and may produce short-term cognitive and neuropsychiatric gains in mild to moderate AD 1. However, this same high-quality review emphasizes that marked protocol heterogeneity, small sample sizes, short follow-up periods, and risk of bias prevent definitive conclusions about optimal parameters.
The strongest meta-analytic evidence shows rTMS significantly improves both immediate cognition (effect size 0.93) and long-term cognition (effect size 0.42) in patients with AD and MCI 2. These improvements have been documented on validated scales including MMSE, MoCA, and ADAS-Cog, with benefits persisting at follow-up in some studies 1, 2.
Optimal Treatment Parameters
Based on the 2025 meta-analysis examining specific protocol variables 2:
For immediate cognitive improvement, use:
- Target site: Dorsolateral prefrontal cortex (DLPFC)
- Frequency: 10-20 Hz (high-frequency stimulation)
- Intensity: ≤80% of motor threshold
- Total treatment time: ≥800 minutes
- Number of sessions: >20 sessions
- Duration: 4-12 weeks, at least 5 days per week
High-frequency protocols (10-20 Hz) consistently outperform low-frequency (1-2 Hz) stimulation 3, 4. The 2022 head-to-head comparison showed high-frequency TMS produced significantly better outcomes on BEHAVE-AD, ADL, and MMSE scores compared to low-frequency stimulation 3.
Patient Selection Considerations
Patients most likely to benefit:
- Mild to moderate AD (not severe dementia) 4
- MCI patients appear to benefit more than those with established AD 5
- Higher educational level correlates with better response 4
The 2026 personalization framework highlights a critical caveat: significant brain atrophy in dementia patients may require individualized dosing adjustments, as standard protocols may deliver insufficient current intensity to target regions 6. This structural variability explains why response rates remain around 50% with standardized approaches.
Adjunctive Strategies
rTMS combined with concurrent cognitive training appears more effective than rTMS alone 4. Stimulation of multiple sites rather than single-site targeting also produces superior cognitive enhancement 4.
Safety Profile
rTMS is generally safe and well-tolerated in AD populations 1, 2. Reported adverse effects are mild to moderate and transient, including:
- Headache
- Scalp discomfort or pain
- Skin itching or burning
- Fatigue
The seizure risk is medium compared to other non-invasive brain stimulation techniques 6.
Critical Limitations
Despite promising signals, rTMS cannot be recommended for routine AD care because:
- Substantial heterogeneity in protocols prevents identification of truly optimal parameters 1
- Small sample sizes and short follow-up periods limit certainty 1
- Long-term efficacy beyond a few months remains unproven
- No standardized protocols exist for clinical implementation
- The "one-size-fits-all" approach fails to account for individual brain atrophy patterns 6
Clinical Bottom Line
rTMS shows promise as an adjunctive treatment for cognitive impairment in mild to moderate AD, but larger sham-controlled trials with standardized protocols, biomarker outcomes, and long-term follow-up are needed before it can be incorporated into standard practice 1. Current use should be limited to research settings or specialized centers capable of protocol individualization based on neuroimaging guidance 6.